Výsledky vyhledávání - "Piotr Szczesny"

Akademický článek

Screening for Anti-HMGCR Antibodies in a Large Single Myositis Center Reveals Infrequent Exposure to Statins and Diversiform Presentation of the Disease

Autor: Piotr Szczesny, Simone Barsotti, Inger Nennesmo, Olof Danielsson, Maryam Dastmalchi

Publikováno v: Frontiers in Immunology, Vol 13 (2022)

BackgroundThe objective of this study is to assess the frequency of autoantibodies against 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) in a single center myositis cohort and to analyze associations with statin exposure, clinical features

Externí odkaz: https://doaj.org/article/300a48f7ac4b4ec4b0fb51eee6fb048a

Zobrazit plný text záznamu

Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers

Autor: Michael Derks, Christoph Wandel, Sian Lennon-Chrimes, Axel Paehler, Piotr Szczesny, Heidemarie Kletzl, Lisa Squassante, Andreas Guenther

Publikováno v: Expert Opinion on Investigational Drugs. 30:893-901

Balovaptan is a potent, selective vasopressin 1a receptor antagonist. The early-phase pharmacokinetics (PK) of balovaptan are reported.Two Phase 1 studies (overallAbsolute balovaptan bioavailability was high (103-116%). Steady-state (Day 14) balovapt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::594453fb8d9e29e6cd63b0245011308f
https://doi.org/10.1080/13543784.2021.1948009

Zobrazit plný text záznamu

Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema

Autor: Jayashree Sahni, Charles C. Wykoff, Dietmar Schwab, Meike Pauly-Evers, Sascha Fauser, Vrinda S. Hershberger, Everson Nogoceke, Arshad M. Khanani, Piotr Szczesny, Sunil S. Patel, Shamil Sadikhov, Aaron Osborne, Chirag Jhaveri, Pravin U. Dugel, Robert James Weikert

Publikováno v: Ophthalmology. 126:1155-1170

Purpose The phase 2 BOULEVARD trial compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients with diabetic macular edema (DME). Des

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::52d085192f792ef6b6bd2006eea8a0fa
https://doi.org/10.1016/j.ophtha.2019.03.023

Zobrazit plný text záznamu

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial

Autor: Dietmar Schwab, Sascha Fauser, Marta del Valle Rubido, Jayashree Sahni, Brian Berger, Pravin U. Dugel, Piotr Szczesny, Everson Nogoceke, Shamil Sadikhov, Mark Chittum, Robert James Weikert, Sunil S. Patel

Publikováno v: JAMA Ophthalmol

Importance Faricimab, the first bispecific antibody designed for intraocular use, simultaneously and independently binds and neutralizes angiopoietin 2 (Ang-2) and vascular endothelial growth factor A (VEGF-A). Objective To assess the efficacy and sa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e6e01282ae67baeb857c29f0bd4609e
https://pubmed.ncbi.nlm.nih.gov/32729888

Zobrazit plný text záznamu

Phase I Trial of Anti–Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration

Autor: Paul Delmar, Adnan Tufail, Peter A. Campochiaro, Anne Boulay, Paul A. Yates, Dietmar Schwab, Sandra Nagel, Usha Chakravarthy, David M. Brown, Jayashree Sahni, Karl G. Csaky, Piotr Szczesny, Mylene Giraudon, Mark Chittum, Clare Bailey, Sabine Fürst-Recktenwald, Patrick Cech

Publikováno v: Ophthalmology Retina. 1:474-485

Purpose RG7716 is a novel bispecific antibody that simultaneously binds vascular endothelial growth factor (VEGF) and another key angiogenic factor, angiopoietin 2. A phase I study of intravitreal RG7716 was conducted to evaluate single-dose and mult

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::add3756ea473b4d16cd6de16c4d80f8f
https://doi.org/10.1016/j.oret.2017.03.003

Zobrazit plný text záznamu

Advancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space

Autor: Hongwen Rivers, Karoline Bechtold-Peters, Hanns-Christian Mahler, Dhananjay Jere, Swati Gupta, Valerie Quarmby, Meg Ferrell Ramos, Sharmila Masli, Eric Wakshull, Piotr Szczesny

Publikováno v: The AAPS Journal. 19:1656-1668

Therapeutic breakthroughs in a number of retinal degenerative diseases have come about through the development of biotherapeutics administered directly into the eye. As a consequence of their use, we have gained more insight into the immune privilege

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03043ab908f4a3dde8b54fe83086512f
https://doi.org/10.1208/s12248-017-0128-y

Zobrazit plný text záznamu

Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial

Autor: Jayashree, Sahni, Sunil S, Patel, Pravin U, Dugel, Arshad M, Khanani, Chirag D, Jhaveri, Charles C, Wykoff, Vrinda S, Hershberger, Meike, Pauly-Evers, Shamil, Sadikhov, Piotr, Szczesny, Dietmar, Schwab, Everson, Nogoceke, Aaron, Osborne, Robert, Weikert, Sascha, Fauser

Publikováno v: Ophthalmology. 126(8)

The phase 2 BOULEVARD trial compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients with diabetic macular edema (DME).The BOULEVAR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::db2d62c94164af7b55c3eb69e9379049
https://pubmed.ncbi.nlm.nih.gov/30905643

Zobrazit plný text záznamu

The Potential Clinical Relevance of Visible Particles in Parenteral Drugs

Autor: Hanns-Christian Mahler, Anja Langenkamp, Piotr Szczesny, Joerg Herrmann, Joseph Famulare, Georg Kallmeyer, Lucette Doessegger, Helmut Rockstroh

Publikováno v: Journal of Pharmaceutical Sciences. 101:2635-2644

Visible particulates (VP) are one subclass of defects seen during the final visual inspection of parenteral products and are currently one of the top ten reasons for recalls 1,2. The risk posed by particles is still unclear with limited experience re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fee2b054696b19c411a7dc934fadc36
https://doi.org/10.1002/jps.23217

Zobrazit plný text záznamu

Translation strategy for the qualification of drug-induced vascular injury biomarkers

Publikováno v: TOXICOLOGIC PATHOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Drug-induced vascular injury (DIVI) is a common preclinical toxicity usually characterized by hemorrhage, vascular endothelial and smooth muscle damage, and inflammation. DIVI findings can cause delays or termination of drug candidates due to low saf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::582cc71f25a4bfc205b73f97c17f1835
https://pubmed.ncbi.nlm.nih.gov/24771082

Zobrazit plný text záznamu

[Morphological analysis of age-related changes in the human choroid]

Autor: Beata, Rymgayłło-Jankowska, Piotr, Szczesny, Zbigniew, Zagórski

Publikováno v: Klinika oczna. 104(5-6)

To investigate morphologic age-related changes in the human choroid and quantify choriocapillaris density and diameter, Bruch's membrane and entire choroid thickness.45 human eyes (aged from 17 to 84) were examined. After fixation of the eyeballs, cr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0aa203fdb97cc28292a8c03a83c9b46b
https://pubmed.ncbi.nlm.nih.gov/12664473

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání